Exploratory study of comparison between fluorescence diagnosis and pathology of mesothelioma

Exploratory study of comparison between fluorescence diagnosis and pathology of mesothelioma - Fluorescence diagnosis of mesothelioma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020266

Enrollment

Registered

2015-12-18

Start date

2016-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mesothelioma Benign Asbestos Pleural Effusion

Interventions

Aminolevulinic acid 20mg/kg at the exam day, p.o.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Benign asbestos pleural effusion with a history of asbestos exposure Mesothelioma suspected by chest CT, FDG-PET or cytology of pleural effusion with a history of asbestos exposure

Exclusion criteria

Exclusion criteria: 1. Cases of pregnancy or lactation 2. Patients with porphyria 3. Patients with chronic hepatitis, chronic renal failure 4. Cases cannot be obtained the consent of the study 5. Cases that have a clear inflammation findings 6. Patients with a history of drug allergy 7. Patients within consent before obtaining four weeks participating in other clinical trials. 8. Cases with inappropriate to join the study decided by the research investigators

Design outcomes

Primary

Measure	Time frame
To compare the sensitivity of the mesothelioma detection per biopsy tissue between fluorescence diagnostics and white light diagnosis.	—

Secondary

Measure	Time frame
1.To compare successful diagnostic rate of mesothelioma between fluorescent diagnosis and historical control with white light diagnosis 2.To examine the pathological tissue in the biopsy specimen of the fluorescent diagnosis 3.To compare the ratio of tumor lesion area per biopsy tissue area between the fluorescence diagnosis and white light diagnosis. 4. To examine pathological findings of benign asbestos pleural effusion example. 5.To examine the safety of the fluorescence diagnosis of mesothelioma using 5-ALA.	—

Measure

Time frame

1.To compare successful diagnostic rate of mesothelioma between fluorescent diagnosis and historical control with white light diagnosis 2.To examine the pathological tissue in the biopsy specimen of the fluorescent diagnosis 3.To compare the ratio of tumor lesion area per biopsy tissue area between the fluorescence diagnosis and white light diagnosis. 4. To examine pathological findings of benign asbestos pleural effusion example. 5.To examine the safety of the fluorescence diagnosis of mesothelioma using 5-ALA.

—

Countries

Japan

Contacts

Public ContactKaori Onishi

Asahikawa Medical University Respiratory Center

k-onishi@asahikawa-med.ac.jp0166-69-3290

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026